Project Grant R43AG084431
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$485K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Katy, TX 77494, USA
Similar Awards
This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
Phenovista Biosciences LLC received a $749,700 Project Grant award from the National Institutes of Health's National Institute on Aging under the Aging Research program (CFDA 93.866) for the period February 1, 2021 through August 31, 2021. The award will support Phenovista's development, validation, and commercialization of a suite of high-throughput, high-content functional assays using human induced pluripotent stem cell-derived microglia models for Alzheimer's disease drug screening. The...
This $1,215,000 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to characterize the genetic architecture underlying the age of amyloid-beta (Aβ) positivity onset in Alzheimer's disease (AD). The award recipient, Mayo Clinic Arizona, will leverage advanced imaging and genetic analysis techniques, including artificial intelligence models, to analyze Aβ positron emission tomography (PET) data from over 16,000 participants in the AD...
This $1,041,646 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports the early clinical development of modified P8 (MP8), a novel peptide drug candidate for the treatment of Alzheimer's disease. The grant recipient, Cenna Biosciences Inc., aims to conduct activities to support a first-in-human clinical study of MP8, including chemistry, manufacturing, and controls (CMC) work, a pre-IND meeting with the FDA, IND application submission,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...
The National Institutes of Health's National Institute on Aging awarded a $7,432,562 project grant to the Regents of the University of California, San Francisco on September 15, 2022 under the Aging Research program (CFDA 93.866). The grant will support research to elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes through 2025. Specifically, the University of California, San Francisco will use CRISPR and single-cell RNA sequencing...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $663,376 to The Regents of the University of California, San Francisco to explore the molecular mechanisms underlying the heterogeneity of Alzheimer's disease and related dementias. The project aims to identify key genes that mediate the selective vulnerability of brain regions to distinct pathological protein conformers, such as tau and alpha-synuclein, using a novel computational modeling...